National Bank Financial reaffirmed their outperform market weight rating on shares of Knight Therapeutics Inc (TSE:GUD) in a research note released on Thursday.

Several other equities analysts have also recently issued reports on the stock. TD Securities reaffirmed a buy rating and issued a C$12.50 price objective on shares of Knight Therapeutics in a research note on Thursday, February 9th. CIBC lowered their price objective on shares of Knight Therapeutics from C$13.00 to C$9.80 in a research note on Friday, January 13th. Mackie cut shares of Knight Therapeutics from a buy rating to a hold rating and lowered their price objective for the stock from C$12.00 to C$10.75 in a research note on Wednesday, January 4th. Finally, Scotiabank lifted their price objective on shares of Knight Therapeutics from C$10.00 to C$10.50 and gave the stock an outperform rating in a research note on Friday, December 23rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of C$11.16.

Knight Therapeutics (TSE:GUD) traded down 0.20% during trading on Thursday, reaching $10.18. 39,198 shares of the company’s stock were exchanged. Knight Therapeutics has a 52 week low of $7.20 and a 52 week high of $11.03. The company’s 50 day moving average price is $10.57 and its 200-day moving average price is $9.90. The stock has a market capitalization of $1.35 billion and a price-to-earnings ratio of 71.69.

Your IP Address:

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.

Receive News & Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.